Drug Trial Radar · NCT01705977
Belimumab Assessment of Safety in SLE
Last checked: Nov 20, 2026Latest source record: Jul 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4,019
Actual
Start
Nov 27, 2012
Primary completion
Jul 30, 2018
Study completion Aug 10, 2022
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Oct 15, 2012
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to further enhance the existing knowledge regarding the side effects of belimumab when given with other lupus medicines to adults with active systemic lupus erythematosus (SLE). This study mainly focuses on collecting information on serious events that are not that common or may only be seen with long-term treatment. These events include death, serious infections and other infections of interest, cancers, serious mental health problems, including depression and suicide, and serious infusion and hypersensitivity reactions. This study is being done to help understand if treatment with belimumab increases the risk for these types of events. This study will also see if patients receiving belimumab with other lupus medicines can reduce their use of steroids, such as prednisone, over 1 year.
Conditions
- Systemic Lupus Erythematosus
Interventions
Placebo plus standard therapyBiological
Placebo plus standard therapy
Belimumab 10 mg/kg plus standard therapyBiological
Belimumab 10 mg/kg plus standard therapy
Standard therapyOther
Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressives; other biologics are not permitted.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Deaths - On Treatment Period (Week 52)Time frame: Up to Week 52 (On-treatment period)
- Number of Participants Who Reported Protocol Defined Adverse Events of Special Interest (AESI): On-treatment Period (Week 52)Time frame: Up to Week 52 (On-treatment period)
- Number of Participants With Serious Adverse Events (SAEs) Reported During On-treatment Period (Week 52)Time frame: Up to Week 52 (On-treatment period)
Locations
250 sites in 33 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Anniston, Alabama
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Huntsville, Alabama
GSK Investigational Site
Glendale, Arizona
GSK Investigational Site
Mesa, Arizona
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Covina, California
GSK Investigational Site
Huntington Beach, California
GSK Investigational Site
La Mesa, California
GSK Investigational Site
Long Beach, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Murrieta, California
GSK Investigational Site
Sacramento, California
GSK Investigational Site
San Leandro, California
GSK Investigational Site
Clearwater, Florida
GSK Investigational Site
Hialeah, Florida
GSK Investigational Site
Tampa, Florida
GSK Investigational Site
Cedar Rapids, Iowa
GSK Investigational Site
Saint Clair Shores, Michigan
GSK Investigational Site
West Bloomfield, Michigan
GSK Investigational Site
Jackson, Mississippi
GSK Investigational Site
Kalispell, Montana
GSK Investigational Site
Las Vegas, Nevada
GSK Investigational Site
New York, New York
GSK Investigational Site
New York, New York
GSK Investigational Site
Chapel Hill, North Carolina
GSK Investigational Site
Charlotte, North Carolina
GSK Investigational Site
Charlotte, North Carolina
GSK Investigational Site
Cincinnati, Ohio
GSK Investigational Site
Columbus, Ohio
GSK Investigational Site
Duncansville, Pennsylvania
GSK Investigational Site
Wyomissing, Pennsylvania
GSK Investigational Site
Orangeburg, South Carolina
GSK Investigational Site
Rock Hill, South Carolina
GSK Investigational Site
Summerville, South Carolina
GSK Investigational Site
Hixson, Tennessee
GSK Investigational Site
Memphis, Tennessee
GSK Investigational Site
Cypress, Texas
GSK Investigational Site
Dallas, Texas
Showing 40 of 250 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.